Results 21 to 30 of about 5,756 (158)

The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients

ESC Heart Failure, 2021
Aims Ivabradine has been used in patients who have chronic heart failure (HF) with reduced ejection fraction (HFrEF) and concomitant sinus heart rate ≥70 bpm. This administration for acute HFrEF remains a concern. This study used a real‐world multicentre
Chia‐Te Liao, Jin‐Long Huang, Huai‐Wen Liang, Fa‐Po Chung, Ying‐Hsiang Lee, Po‐Lin Lin, Wei‐Ru Chiou, Wen‐Yu Lin, Chien‐Yi Hsu, Hung‐Yu Chang   +9 more
doaj   +1 more source

A pilot study evaluating the role of ivabradine for rate control in patients with rheumatic atrial fibrillation

Indian Heart Journal, 2023
Objectives: Ivabradine may have a role in rate control of atrial fibrillation (AF) due to effects on HCN channels in AV node. We studied role of Ivabradine in rate control of rheumatic AF. Methods: 80 patients, rheumatic AF, HR > 100 bpm (age 47 ± 11 yrs,
Arpita Katheria, Aditya Kapoor, Ankit Sahu, Kamlesh Raut, Harshit Khare, Roopali Khanna, Sudeep Kumar, Naveen Garg, Satyendra Tewari   +8 more
doaj   +1 more source

Ivabradine Reduces Chemokine-Induced CD4-Positive Lymphocyte Migration

Mediators of Inflammation, 2010
Aims. Migration of CD4-positive lymphocytes into the vessel wall is a critical step in atherogenesis. Recent data suggest that ivabradine, a selective I(f)-channel blocker, reduces atherosclerotic plaque formation in apolipoprotein E-deficient mice ...
Thomas Walcher, Peter Bernhardt, Dusica Vasic, Helga Bach, Renate Durst, Wolfgang Rottbauer, Daniel Walcher   +6 more
doaj   +1 more source

Locally injected ivabradine inhibits carrageenan-induced pain and inflammatory responses via hyperpolarization-activated cyclic nucleotide-gated (HCN) channels.

PLoS ONE, 2019
BackgroundRecently, attention has been focused on the role of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in the mechanism of and as a treatment target for neuropathic and inflammatory pain.
Saki Miyake, Hitoshi Higuchi, Yuka Honda-Wakasugi, Maki Fujimoto, Hotaka Kawai, Hitoshi Nagatsuka, Shigeru Maeda, Takuya Miyawaki   +7 more
doaj   +1 more source

Ectopic Atrial Tachycardia in a 12-Month-Old Girl Treated With Ivabradine and Beta-Blocker, a Case Report

Frontiers in Pediatrics, 2020
We report on a 12-month-old girl with an ectopic atrial tachycardia successfully treated with the combination of a beta blocking agent and Ivabradine that acts on cardiac pacemaker cells by selectively inhibiting the If channel.
Holger Michel, Frank Heißenhuber, Sven Wellmann, Michael Melter, Stephan Gerling   +4 more
doaj   +1 more source

Preserved Autonomic Cardiovascular Regulation With Cardiac Pacemaker Inhibition: A Crossover Trial Using High‐Fidelity Cardiovascular Phenotyping

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundSympathetic and parasympathetic influences on heart rate (HR), which are governed by baroreflex mechanisms, are integrated at the cardiac sinus node through hyperpolarization‐activated cyclic nucleotide–gated channels (HCN4).
Karsten Heusser, Jens Tank, Julia Brinkmann, Christoph Schroeder, Marcus May, Anika Großhennig, Daniela Wenzel, André Diedrich, Fred C. G. J. Sweep, Heidrun Mehling, Friedrich C. Luft, Jens Jordan   +11 more
doaj   +1 more source

Ivabradine Prevents Low Shear Stress Induced Endothelial Inflammation and Oxidative Stress via mTOR/eNOS Pathway. [PDF]

PLoS ONE, 2016
Ivabradine not only reduces heart rate but has other cardiac and vascular protective effects including anti-inflammation and anti-oxidation. Since endothelial nitric oxide synthase (eNOS) is a crucial enzyme in maintaining endothelial activity, we aimed ...
Bing Li, Junxia Zhang, Zhimei Wang, Shaoliang Chen   +3 more
doaj   +1 more source

Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure

Journal of Immunology Research, 2016
Background. Inflammation plays a crucial role in the progression of chronic heart failure (CHF). Ivabradine is known to reduce the morbidity and mortality of patients with CHF under certain conditions.
Ilonka Rohm, Daniel Kretzschmar, Rudin Pistulli, Marcus Franz, P. Christian Schulze, Christian Stumpf, Atilla Yilmaz   +6 more
doaj   +1 more source

Identification of the molecular site of ivabradine binding to HCN4 channels.

PLoS ONE, 2013
Ivabradine is a specific heart rate-reducing agent approved as a treatment of chronic stable angina. Its mode of action involves a selective and specific block of HCN channels, the molecular components of sinoatrial "funny" (f)-channels.
Annalisa Bucchi, Mirko Baruscotti, Marco Nardini, Andrea Barbuti, Stefano Micheloni, Martino Bolognesi, Dario DiFrancesco   +6 more
doaj   +1 more source

Clinical use of ivabradine in the acute coronary syndrome: A systematic review and narrative synthesis of current evidence

American Heart Journal Plus, 2022
Heart rate (HR) lowering during acute coronary syndrome (ACS) is beneficial as it reduces myocardial oxygen consumption. However, the role of ivabradine as an HR-lowering agent in the setting of ACS is not clear.
Josip A. Borovac, Martin Kowalski, Tina Poklepovic Pericic, Marin Vidak, Konstantin Schwarz, Domenico D'Amario, Dino Miric, Duska Glavas, Josko Bozic   +8 more
doaj   +1 more source